Drug intelligence / Profile preview

elacycline

Development stage: Preclinical
Lead developer: Talphera
Modality: Small Molecules
Administration: Intravenous

Overview

Elacycline is a synthetic tetracycline-class antibiotic. It is structurally related to eravacycline and other fluorocyclines, designed to overcome bacterial resistance mechanisms common in traditional tetracyclines. Elacycline acts by binding to the 30S ribosomal subunit of bacteria, inhibiting protein synthesis and thereby killing or stopping the growth of susceptible bacteria. It is being developed for the treatment of complicated intra-abdominal infections and other serious bacterial infections caused by multidrug-resistant pathogens.

Other names: elacycline

Targets

30S A-site (Bacterial ribosomal 30S A-site)

Beyond the preview

Go deeper on elacycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on elacycline.

Explore the full profile